×
About 15,413 results

ALLMedicine™ Chronic Lymphocytic Leukemia Center

Research & Reviews  4,587 results

Identifying patients with chronic lymphocytic leukemia without need of treatment (CLL-W...
https://doi.org/10.1111/ejh.13743
European Journal of Haematology; Brieghel C, Galle V et. al.

Jan 15th, 2022 - Early stage chronic lymphocytic leukemia (CLL) challenges specialized management and follow-up. We developed and validated a prognostic index to identify newly diagnosed patients without need of treatment (CLL-WONT) by a training/validation approa...

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT02029443

Jan 14th, 2022 - This study is evaluating the safety and efficacy of a new Bruton tyrosine kinase (Btk) inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03624036

Jan 14th, 2022 - The primary objective of this study is to evaluate the safety and tolerability of brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory chronic lymphocytic leukemia (r/r CLL) and small lymphocytic lymphoma (r/r SLL). After the end...

B cell antigen receptor expression and phosphatidylinositol 3-kinase signaling regulate...
https://doi.org/10.3324/haematol.2021.279924
Haematologica Schmid VK, Khadour A et. al.

Jan 14th, 2022 - Chronic lymphocytic leukemia (CLL) is a frequent lymphoproliferative disorder of B cells. Although inhibitors targeting signal proteins involved in B cell antigen receptor (BCR) signaling constitute an important part of the current therapeutic pro...

see more →

Guidelines  8 results

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical ...
https://doi.org/10.6004/jnccn.2020.0006
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Byrd JC et. al.

Feb 6th, 2020 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid tissues. Treatment of CLL/SLL has evolved significantly in...

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940638
Leukemia Malcikova J, Tausch E et. al.

Feb 23rd, 2018 - In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with resistance to chemoimmunotherapy and a particularly dismal clinical outcome. On these grounds...

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Vers...
https://doi.org/10.6004/jnccn.2017.0030
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Zelenetz AD et. al.

Mar 10th, 2017 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease and managed in much the same way. The advent of novel CD20 monoclonal antibodies led to the development of effective chemoimmu...

Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841457
Journal of the National Comprehensive Cancer Network : JN... Zelenetz AD, Gordon LI et. al.

Mar 5th, 2015 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the develop...

Non-Hodgkin's lymphomas, version 1.2013.
https://doi.org/10.6004/jnccn.2013.0037
Journal of the National Comprehensive Cancer Network : JN... Zelenetz AD, Wierda WG et. al.

Mar 15th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Non-Hodgkin's Lymphomas (NHL) and provide a discussion of the clinical evidence that support the updates. The updates discussed in this article feature recomme...

see more →

Drugs  43 results see all →

Clinicaltrials.gov  302 results

Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03624036

Jan 14th, 2022 - The primary objective of this study is to evaluate the safety and tolerability of brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory chronic lymphocytic leukemia (r/r CLL) and small lymphocytic lymphoma (r/r SLL). After the end...

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT02029443

Jan 14th, 2022 - This study is evaluating the safety and efficacy of a new Bruton tyrosine kinase (Btk) inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
https://clinicaltrials.gov/ct2/show/NCT03207256

Jan 13th, 2022 - This is an open label compassionate use trial of Ublituximab and TGR-1202 in combination or as single agents in patients currently receiving treatment on Ublituximab and/or TGR-1202 trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic ...

Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT02756897

Jan 12th, 2022 - PRIMARY OBJECTIVE: I. Estimate therapeutic activity (best response [complete response (CR)/complete response with incomplete recovery (CRi)]) of combined ibrutinib and venetoclax in patients with chronic lymphocytic leukemia (CLL)/small lymphocyti...

Testing the Effects of Early Treatment With Venetoclax and Obinutuzumab Versus Delayed Treatment With Venetoclax and Obinutuzumab for Newly Diagnosed Patients With High-Risk Chronic Lymphocytic Leu...
https://clinicaltrials.gov/ct2/show/NCT04269902

Jan 12th, 2022 - PRIMARY OBJECTIVE: I. To evaluate whether early treatment with venetoclax and obinutuzumab (V-O) extends overall survival (OS) compared with delayed treatment with V-O in high-risk (Chronic Lymphocytic Leukemia [CLL] International Prognostic Indic...

see more →

News  1,216 results

Rapid Readout: Pirtobrutinib, A Highly Selective, Noncovalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study
https://www.onclive.com/view/pirtobrutinib-a-highly-selective-non-covalent-reversible-btk-inhibitor-in-previously-treated-cll-sll-updated-results-from-the-phase-1-2-bruin-study

Jan 14th, 2022 - Anthony Mato, MD, discusses data from the following presentation: Updated results from the phase 1/2 BRUIN study of the noncovalent BTK inhibitor (BTKi) pirtobrutinib in patients with previously treated chronic lymphocytic leukemia/small lymphocy...

Zanubrutinib Improves PFS in Treatment-Naïve CLL/SLL
https://www.onclive.com/view/zanubrutinib-improves-pfs-in-treatment-na-ve-cll-sll

Jan 14th, 2022 - Zanubrutinib (Brukinsa) elicited a statistically significant improvement in progression-free survival (PFS) vs the combination of bendamustine and rituximab (Rituxan; BR) in patients with treatment-naïve chronic lymphocytic leukemia (CLL) and smal...

COVID-19 Vaccine Responses Vary Among Hematological Malignancies
https://www.medscape.com/viewarticle/966288

Jan 8th, 2022 - Key Takeaways The primary outcome was the rate of seropositivity after 2 doses of a COVID-19 vaccine with rates of seropositivity after 1 dose, rates of positive neutralizing antibody (nAb), cellular responses and adverse events as secondary outco...

Dr. Choi on the Long-Term Efficacy of Frontline Ibrutinib in CLL
https://www.onclive.com/view/dr-choi-on-the-long-term-efficacy-of-frontline-ibrutinib-in-cll

Jan 6th, 2022 - Michael Choi, MD, hematologist/medical oncologist, associate professor of medicine, Moores Cancer Center, University of California San Diego Health, discusses the long-term efficacy of ibrutinib (Imbruvica) given as a frontline treatment in chroni...

Expansion Cohort Explores Efficacy of Novel Treatment for Waldenström Macroglobulinemia
https://www.onclive.com/view/expansion-cohort-explores-efficacy-of-novel-treatment-for-waldenstr-m-macroglobulinemia

Jan 5th, 2022 - Treatment options for patients with Waldeström macroglobulinemia (WM) are often derived from those developed for patients with multiple myeloma and other low-grade lymphomas. Patients with WM are relatively rare. Their disease is defined as lympho...

see more →

Patient Education  9 results see all →